Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.94 which represents a decrease of $-0.55 or -2.56% from the prior close of $21.49. The stock opened at $21.27 and ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.49 which represents a decrease of $-0.11 or -0.51% from the prior close of $21.6. The stock opened at $21.59 and ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...

TEV-56278 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Solid Tumor.

In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...

TEV-56192 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Unspecified Neurologic Disorders.

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...

We recently compiled a list of the 10 Firms Kick Off 2025 Trading in The Red. In this article, we are going to take a look at ...

Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.75 and a fifty-two week high of $22.80. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ...